Abstract:Background Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells with a remarkable ability to suppress the immune system. Although MDSCs were found to suppress the T cell response of some cancer patients and tumour bearing mice, the role of those cells have been revealed in patients with RA, SLE, and IBD. Nevertheless, most rheumatic diseases have a common pathological process, such as inflammatory arthritis and systemic tissue damage. Whether or not MDSCs and their subsets are abnormally expressed in patients with inflammatory-associated rheumatic diseases is still unclear. Objectives To investigate the proportion of MDSCs and their subsets in patients with different rheumatic diseases and clarify the association between those cells and patients clinical data including the disease activity index and the inflammation of joints. Methods One hundred and nine patients with various rheumatic diseases and twenty-five healthy controls were recruited. The common clinical characteristics and the special clinical indexes for each rheumatic disease were obtained from patients. The MDSCs and their subsets were marked with fluorescently labelled antibodies and were then analysed with flow cytometry. All statistics were calculated with SPSS 20.0. A p<0.05 was considered to be statistically significant. Results The patients included 31 with RA, 21 with AS, 14 with OA, 11 with SLE with arthritis, 13 with SLE without arthritis, 9 with Gout, 10 with HUA, and 25 healthy controls. The proportions of MDSCs, M-MDSCs, and G-MDSCs were higher in patients with RA than in healthy controls (6.56%±6.77% vs. 1.46±0.96%, 2.52±3.81% vs. 0.35±0.35%, 1.13±1.64% vs. 0.18±0.14%; p<0.001). The same increase in the number of MDSCs and their subsets was also found in patients with AS, OA, SLE with arthritis, and Gout. The proportions of MDSCs and M-MDSCs were mostly correlated with the patient‘s joint inflammation indexes (such as CRP and total joint pain) and the disease activity. Additionally, an increased risk of arthritis was found from MDSCs, M-MDSCs, and G-MDSCs (OR=2.417, 13.257, 6.204; 95% CI=1.625–3.597, 3.974–44.223, 1.798–21.406; p<0.01). When other cell subsets were adjusted, the same risk was also obtained for the expansion of M-MDSCs (adjusted OR=5.772; 95% CI 1.174–28.369; p=0.031). Conclusions The expansion of MDSCs and their subsets were found to be correlated with the disease activity and joint inflammation in patients with different rheumatic diseases. Further analysis revealed that the proportion of M-MDSCs was associated with the risk of arthritis in those populations. Acknowledgements Supported by the Natural Science Foundation of Guangdong ProvinceNo. 2017A030313868), and the President Foundation of Nanfang Hospital, Southern Medical UniversityNo. 2016C024). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Disclosure of Interest None declared

Myeloid-derived suppressor cells contribute to systemic lupus erythematosus by regulating differentiation of Th17 cells and Treg.

Dysregulated T Cell Activation and Aberrant Cytokine Expression Profile in Systemic Lupus Erythematosus.

Mdscs Enhance Th17 Differentiation and Disease Progression Through Arginase-1 Production in Patients with Systemic Lupus Erythematosus

Arginase-1–dependent Promotion of T H 17 Differentiation and Disease Progression by MDSCs in Systemic Lupus Erythematosus

MDSC-derived S100A8/9 contributes to lupus pathogenesis by promoting TLR7-mediated activation of macrophages and dendritic cells

Myeloid-derived suppressor cells shift Th17/Treg ratio and promote systemic lupus erythematosus progression through arginase-1/miR-322-5p/TGF- pathway

Myeloid-Derived Suppressor Cells Shift Th17/Treg Ratio And Promote Systemic Lupus Erythematosus Progression Through Arginase-1/Mir-322-5p/Tgf-Beta Pathway

Myeloid-derived suppressor cells exacerbate Sjögren's syndrome by inhibiting Th2 immune responses.

FoxO1 Deficiency in Monocytic Myeloid-Derived Suppressor Cells Exacerbates B Cell Dysfunction in Systemic Lupus Erythematosus.

Polyamines from myeloid-derived suppressor cells promote Th17 polarization and disease progression

FoxO1 Deficiency in M‐MDSCs Exacerbates B Cell Dysfunction in Systemic Lupus Erythematosus

Myeloid-derived Suppressor Cells and Multiple Sclerosis

The Regulation of the Treg/Th17 Balance by Mesenchymal Stem Cells in Human Systemic Lupus Erythematosus

AB1321 the Expansion of Myeloid-Derived Suppressor Cells in Patients with Rheumatic Diseases

AB0160 Loss of Let-7 Microrna Upregulates Il-6 in Bone Marrow-Derived Mesenchymal Stem Cells Triggering Treg/th17 Imbalance in Patients with Systemic Lupus Erythematosus

Myeloid-derived suppressor cell: A crucial player in autoimmune diseases

Myeloid-derived Suppressive Cells Enhance Differentiation of Th17 Cells in an IL-1β Dependent Manner (P1096)

Myeloid-Derived Suppressor Cells Have A Proinflammatory Role in the Pathogenesis of Autoimmune Arthritis

MDSCs Participate in the Pathogenesis of Diffuse Pulmonary Hemorrhage in Murine Lupus Through Mtor-Foxo1 Signaling

Mesenchymal Stem Cell Transplantation Alleviated Atherosclerosis in Systemic Lupus Erythematosus Through Reducing MDSCs

IRF-8/miR-451a regulates M-MDSC differentiation via the AMPK/mTOR signal pathway during lupus development